# Jubilant Therapeutics

Source: https://onco.cc/companies/jubilant-therapeutics/  
OnCo record `jubilant-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jubilant Therapeutics, part of India's Jubilant group, designs small molecules that hit two epigenetic targets at once; JBI-802 inhibits both LSD1 and HDAC6 for myeloproliferative neoplasms and small cell lung cancer.

## Summary

Jubilant Therapeutics is a precision-medicine subsidiary of Jubilant Pharmova that uses structure-based design to make dual-action small molecules. JBI-802 is an oral inhibitor of the epigenetic enzymes LSD1 and HDAC6 in a single molecule, in phase 1/2 trials in essential thrombocythaemia, other myeloproliferative neoplasms and neuroendocrine cancers including small cell lung cancer. Its pipeline also includes a PAD4 inhibitor and PD-L1 small molecules.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Jubilant Therapeutics Inc.
- Tags: drug-maker
- HQ: Bedminster, New Jersey
- Type: biotech
- Website: https://www.jubilanttx.com/

## Sources

- Official website: https://www.jubilanttx.com/

## Connected records

- drugs: [JBI-802](https://onco.cc/drugs/jbi-802/)

---
JSON: https://onco.cc/api/v1/entities/jubilant-therapeutics.json